{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-028339","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.699164+00:00","generated_at":"2026-05-31T06:26:25.639973+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Genprex to spin out diabetes gene therapy program into new subsidiary GPX-002","bullets":["Intends to transfer diabetes clinical development and gene therapy assets to wholly-owned NewCo.","NewCo will focus on GPX-002 for Type 1 and Type 2 diabetes; Genprex retains oncology programs.","Spin-out expected by end of 2024, subject to financing, conditions, and board approval.","Reorganization follows recent refocus on oncology lead Reqorsa Gene Therapy for expedited regulatory submission.","Company continues to evaluate strategic alternatives to enhance stockholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-028339","json":"https://secwatch.observer/filing/0001437749-24-028339.json","markdown":"https://secwatch.observer/filing/0001437749-24-028339.md","text":"https://secwatch.observer/filing/0001437749-24-028339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924028339/0001437749-24-028339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924028339/gnpx20240703_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:26:25.639973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}